Clinical-phase2-trials-NASH-and-obesity

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and ObesityNew studies mark an important advancement of Boehringer Ingelheim ’s cardiometabolic focus areas obesity and NASH.The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on both chronic weight management and NASH improvementThe Phase 2 trials for BI 456906 in obesity and NASH are part of the long-term collaboration between Boehringer Ingelheim and Zealand Pharma, with a prior Phase 2 trial of BI 456906 in people with type 2 diabetes initiated in 2020.  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news